• Indication
    INDICATION

    BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

    • adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • U.S. Full Prescribing Information
  • Prep and Administration
  • REMS
  • Patient Site
  • This site is intended for US healthcare professionals only.
Breyanzi (lisocabtagene maraleucel) logo
  • Treatment Gaps
  • Patient ID
  • Efficacy
  • Safety
  • Process
  • Support
  • Treatment Centers
  • CLL/SLL
    • R/R Large B-Cell Lymphoma (LBCL)
    • R/R Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    • R/R Follicular Lymphoma (FL)
    • R/R Mantle Cell Lymphoma (MCL)
  • Indication
  • U.S. Full Prescribing Information
  • Prep and Administration
  • Patient Site
  • This site is intended for US healthcare professionals only
Site map
  • Treatment Gaps
  • Patient Identification
  • Efficacy
  • Safety
  • Process
  • Support
  • Treatment Centers
Bristol Myers Squibb logo
  • Legal Notice
  • Privacy Policy
  • Your Privacy Choices
  • Site Map
  • Site Map
  • Site Map
  • Site Map
  • Site Map
  • Contact Us

© 20252025 Juno Therapeutics, Inc., a Bristol Myers Squibb company. All Rights Reserved.

BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.

Cell Therapy 360 is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.

Cell Therapy 360 is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

© 20252025 Bristol Myers Squibb company.
2009-US-2300123 2009-US-2400603 2009-US-2400583 2009-US-2400630 2009-US-2400630 2009-US-2400611
09/2023 10/2024 12/2024 10/2024
Back to Top BACK TO TOP